1
|
Dong J, Wang Q, Gu T, Liu G, Petrov YV, Baulin VE, Yu Tsivadze A, Jia D, Zhou Y, Yuan H, Li B. Rapamycin functionalized carbon Dots: Target-oriented synthesis and suppression of vascular cell senescence. J Colloid Interface Sci 2024; 660:534-544. [PMID: 38266335 DOI: 10.1016/j.jcis.2024.01.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/21/2023] [Accepted: 01/05/2024] [Indexed: 01/26/2024]
Abstract
Suppression of vascular cell senescence is of great significance in preventing cardiovascular diseases such as hypertension and atherosclerosis. The oxidative stress damage caused by reactive oxygen species (ROS) can lead to cellular senescence. Rapamycin (Rapa) is well known to suppress cell senescence via mammalian target of rapamycin (mTOR) pathway. However, poor water solubility and lack of ROS scavenging ability limit the further development of Rapa. To improve the solubility of Rapa and endow with ROS scavenging ability, Rapa functionalized carbon dots (Rapa-CDs) are target-oriented synthesized via free radical polymerization combination with hydrothermal carbonization. Rapa-CDs improve the solubility of Rapa and show ROS scavenging abilities. The solubility of Rapa-CDs with 9.41 g is improved 3.6 × 104 times higher than that of Rapa (2.6 × 10-4 g). The half maximal inhibitory concentration (IC50) of Rapa-CDs toward hydroxyl radical (•OH) and 2,2-Diphenyl-1-picrylhydrazyl free radical (DPPH•) are 0.18 and 0.17 mg/mL, respectively. Rapa-CDs show anti-oxidative stress effect in HEVECs (Human Umbilical Vein Endothelial Cells) via reducing ROS levels by 87 %. Rapa-CDs alleviate HUVECs senescence by suppressing mTOR overactivation, attenuate the expression of P53, P21 and P16. The study demonstrates the target-oriented synthesis of drugs functionalized CDs with anti-senescence via dual-pathway of anti-oxidative stress and mTOR.
Collapse
Affiliation(s)
- Jiaxin Dong
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China
| | - Qi Wang
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, PR China
| | - Tingting Gu
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China
| | - Guanxiong Liu
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China
| | - Yuri V Petrov
- Laboratory of Dynamics and Extreme Characteristics of Promising Nanostructured Materials, Saint Petersburg State University, St. Petersburg, 199034, Russia
| | - Vladimir E Baulin
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia; Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences, Moscow, 119071, Russia
| | - Aslan Yu Tsivadze
- Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences, Moscow, 119071, Russia
| | - Dechang Jia
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China
| | - Yu Zhou
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China
| | - Huiping Yuan
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, PR China.
| | - Baoqiang Li
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, PR China; Laboratory of Dynamics and Extreme Characteristics of Promising Nanostructured Materials, Saint Petersburg State University, St. Petersburg, 199034, Russia.
| |
Collapse
|
2
|
Wang Q, Dong J, Du M, Liu X, Zhang S, Zhang D, Qin W, Xu X, Li X, Su R, Qiu L, Li B, Yuan H. Chitosan-Rapamycin Carbon Dots Alleviate Glaucomatous Retinal Injury by Inducing Autophagy to Promote M2 Microglial Polarization. Int J Nanomedicine 2024; 19:2265-2284. [PMID: 38476273 PMCID: PMC10928492 DOI: 10.2147/ijn.s440025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Accepted: 02/22/2024] [Indexed: 03/14/2024] Open
Abstract
Introduction Glaucoma is a prevalent cause of irreversible vision impairment, characterized by progressive retinal ganglion cells (RGCs) loss, with no currently available effective treatment. Rapamycin (RAPA), an autophagy inducer, has been reported to treat glaucoma in rodent models by promoting RGC survival, but its limited water solubility, systemic toxicity, and pre-treatment requirements hinder its potential clinical applications. Methods Chitosan (CS)-RAPA carbon dot (CRCD) was synthesized via hydrothermal carbonization of CS and RAPA and characterized by transmission electron microscopy, Fourier transform infrared spectra, and proton nuclear magnetic resonance. In vitro assays on human umbilical cord vein endothelial and rat retinal cell line examined its biocompatibility and anti-oxidative capabilities, while lipopolysaccharide-stimulated murine microglia (BV2) assays measured its effects on microglial polarization. In vivo, using a mouse retinal ischemia/reperfusion (I/R) model by acute intraocular pressure elevation, the effects of CRCD on visual function, RGC apoptosis, oxidative stress, and M2 microglial polarization were examined. Results CRCD exhibited good water solubility and anti-oxidative capabilities, in the form of free radical scavenging. In vitro, CRCD was bio-compatible and lowered oxidative stress, which was also found in vivo in the retinal I/R model. Additionally, both in vitro with lipopolysaccharide-stimulated BV2 cells and in vivo with the I/R model, CRCD was able to promote M2 microglial polarization by activating autophagy, which, in turn, down-regulated pro-inflammatory cytokines, such as IL-1β and TNF-α, as well as up-regulated anti-inflammatory cytokines, such as IL-4 and TGF-β. All these anti-oxidative and anti-inflammatory effects ultimately aided in preserving RGCs, and subsequently, improved visual function. Discussion CRCD could serve as a potential novel treatment strategy for glaucoma, via incorporating RAPA into CDs, in turn not only mitigating its toxic side effects but also enhancing its therapeutic efficacy.
Collapse
Affiliation(s)
- Qi Wang
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Jiaxin Dong
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, People’s Republic of China
| | - Mengxian Du
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Xinna Liu
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Shiqi Zhang
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Di Zhang
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Wanyun Qin
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Xikun Xu
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People’s Republic of China
| | - Xianghui Li
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| | - Ruidong Su
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People’s Republic of China
| | - Leyi Qiu
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
- The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People’s Republic of China
| | - Baoqiang Li
- Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, People’s Republic of China
- Laboratory of Dynamics and Extreme Characteristics of Promising Nanostructured Materials, Saint Petersburg State University, St. Petersburg, Russia
| | - Huiping Yuan
- Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
| |
Collapse
|
3
|
Sigg N, Fouquet J, Morin D, Farges D, Vrignaud S, Martin L. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin. Ann Dermatol Venereol 2023; 150:270-273. [PMID: 37821253 DOI: 10.1016/j.annder.2023.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 04/14/2023] [Accepted: 06/22/2023] [Indexed: 10/13/2023]
Abstract
AIMS Topical rapamycin is used to reduce facial angiofibromas in patients with tuberous sclerosis (TSC). In the absence of a commercially available preparation, numerous formulations have been tested clinically, although only in the short term. METHODS The pharmacy at Angers University Hospital (France) produced a cream formulation that was administered to people presenting this genetic disease. We conducted a questionnaire-based survey among 79 patients with TSC about their perceptions regarding the short-, medium- and long-term efficacy and safety of a topical rapamycin preparation in relation to facial angiofibromas. RESULTS This formulation was very well tolerated and its efficacy was sustained over the long term with a mean treatment duration of 33 months (extremes 1-60). Efficacy was rated ≥ 8/10 by 67.1% of patients while safety was rated ≥ 8/10 by 84.8% of patients. CONCLUSION This survey supports the safety and efficacy of topical rapamycin in the short-, medium- and long-term in the treatment of facial angiofibromas in a cohort of 79 patients with TSC.
Collapse
Affiliation(s)
- N Sigg
- Dermatology Department, CRMR MAGEC Nord, Angers University Hospital, France.
| | - J Fouquet
- Dermatology Department, CRMR MAGEC Nord, Angers University Hospital, France
| | - D Morin
- Dermatology Department, CRMR MAGEC Nord, Angers University Hospital, France
| | - D Farges
- Dermatology Department, CRMR MAGEC Nord, Angers University Hospital, France
| | - S Vrignaud
- Pharmacy, Angers University Hospital, France
| | - L Martin
- Dermatology Department, CRMR MAGEC Nord, Angers University Hospital, France
| |
Collapse
|
4
|
Balestri R, Rizzoli L, Pedrolli A, Urru SAM, Rech G, Neri I, Girardelli CR, Magnano M. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update. J Eur Acad Dermatol Venereol 2023; 37:474-487. [PMID: 36300771 DOI: 10.1111/jdv.18693] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 10/14/2022] [Indexed: 11/29/2022]
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome causing hamartomatous growths in multiple organs. Facial angiofibromas occur in up to 80% of patients and can be highly disfiguring. Treatment for these lesions is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas but a commercially available compound has not yet been developed in Europe. We conducted a retrospective review with the aim to update the current data on the use of topical rapamycin in the treatment of angiofibromas in TSC, focusing on the optimal concentration and trying to establish which vehicle should be preferred. Thirty-nine reports describing the use of topical rapamycin in the treatment of angiofibromas in TSC were considered, involving a total of 483 patients. An improvement of the lesions has been shown in over 90% of subjects, particularly if the treatment was started at early stages. Several different formulations (ointment, gel, solution and cream) with a wide range of concentrations (0.003%-1%) were proposed, of which a pharmacological analysis has also been performed. Topical rapamycin can be considered an effective and safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has yet to be established. Our review demonstrates that ointment and gel should be preferred, but it is not clear which concentration is optimal. However, according to this study, the 0.1% concentration represents the first choice. Long-term and comparative studies between topical rapamycin formulations are required in order to establish which treatment has a better outcome and lower recurrence rate.
Collapse
Affiliation(s)
- Riccardo Balestri
- Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy
| | - Laura Rizzoli
- Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy
| | - Annalisa Pedrolli
- Division of Pediatrics, Outpatient Consultation for Rare Diseases, Trento, Italy
| | - Silvana Anna Maria Urru
- Hospital Pharmacy Unit, Trento General Hospital, Autonomous Province of Trento, Trento, Italy
| | - Giulia Rech
- Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy
| | - Iria Neri
- Dermatology Unit, IRCSS Policlinico di S. Orsola, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
| | - Carlo R Girardelli
- Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy
| | - Michela Magnano
- Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy
| |
Collapse
|
5
|
Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. Arch Pediatr 2022; 29:5S20-5S24. [PMID: 36585067 DOI: 10.1016/s0929-693x(22)00286-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
BACKGROUND Skin manifestations of Tuberous Sclerosis Complex (TSC) are present in more than 90% of patients. Facial angiofibromas (AF) are considered a skin hallmark of TSC. They are responsible for esthetic impact in patients. We aimed at reviewing the data available on the use of rapamycin (sirolimus) and everolimus for the oral or topical treatment of AF and other TSC-related skin changes and reporting our preliminary experience at Angers University Hospital. METHODS The literature search has been performed in combining the terms "rapamycin", "sirolimus", "everolimus", "tuberous sclerosis complex", "skin" and "trial". We have splited the findings of the literature search into two parts: 1) the value of rapalogs used systemically for extracutaneous purposes and 2) the role of topical rapalogs used specifically for skin lesions. RESULTS Large clinical trials using rapamycin or everolimus for the treatment of brain, lung or kidney manifestations of TSC unfortunately poorly define the "skin lesion response rate" they report. Conversely, the trials with topical rapamycin demonstrate significant, albeit transient, efficacy on AF size and visibility and acceptable tolerance. Several trials suggest better efficacy in younger patients than in adults. Long-term evaluation (up to 136 weeks) point to sustained response and good local and systemic tolerance. However, maintenance therapy appears to be mandatory to preserve skin response. Other skin changes, especially shagreen fibrotic plaques, hypomelanotic macules and ungual tumors still need far more research. Our experience in 124 patients (children and adults) treated for facial AF at Angers University Hospital showed that about 80% of them had an impressive and sustained response. CONCLUSION The issues of cost and access to affordable topical rapamycin formulations are critical for the patients even if skin changes do not cause serious harm in the context of TSC. We strongly suggest to improve and standardize the formulation of topical rapamycin, to encourage the pharmaceutical industry for providing commercial products, and the Health systems (social welfare) to reimburse them. © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
Collapse
|
6
|
Le Guyader G, Do B, Rietveld IB, Coric P, Bouaziz S, Guigner JM, Secretan PH, Andrieux K, Paul M. Mixed Polymeric Micelles for Rapamycin Skin Delivery. Pharmaceutics 2022; 14:pharmaceutics14030569. [PMID: 35335945 PMCID: PMC8948846 DOI: 10.3390/pharmaceutics14030569] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 02/22/2022] [Accepted: 03/01/2022] [Indexed: 12/10/2022] Open
Abstract
Facial angiofibromas (FA) are one of the most obvious cutaneous manifestations of tuberous sclerosis complex. Topical rapamycin for angiofibromas has been reported as a promising treatment. Several types of vehicles have been used hitherto, but polymeric micelles and especially those made of d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) seem to have shown better skin bioavailability of rapamycin than the so far commonly used ointments. To better understand the influence of polymeric micelles on the behavior of rapamycin, we explored it through mixed polymeric micelles combining TPGS and poloxamer, evaluating stability and skin bioavailability to define an optimized formulation to effectively treat FA. Our studies have shown that TPGS improves the physicochemical behavior of rapamycin, i.e., its solubility and stability, due to a strong inclusion in micelles, while poloxamer P123 has a more significant influence on skin bioavailability. Accordingly, we formulated mixed-micelle hydrogels containing 0.1% rapamycin, and the optimized formulation was found to be stable for up to 3 months at 2–8 °C. In addition, compared to hydroalcoholic gel formulations, the studied system allows for better biodistribution on human skin.
Collapse
Affiliation(s)
- Guillaume Le Guyader
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France; (G.L.G.); (M.P.)
- Centre Hospitalier Intercommunal de Créteil, F-94010 Créteil, France
| | - Bernard Do
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France; (G.L.G.); (M.P.)
- Matériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France;
- Correspondence:
| | - Ivo B. Rietveld
- SMS Laboratory (EA 3233), Université de Rouen-Normandie, Place Émile Blondel, 76821 Mont Saint Aignan, France;
- Faculté de Pharmacie, Université de Paris, 4 Avenue de l’Observatoire, 75006 Paris, France
| | - Pascale Coric
- UMR 8038 CiTCoM, CNRS, University of Paris, 75006 Paris, France; (P.C.); (S.B.)
| | - Serge Bouaziz
- UMR 8038 CiTCoM, CNRS, University of Paris, 75006 Paris, France; (P.C.); (S.B.)
| | - Jean-Michel Guigner
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), UMR CNRS 7590, MNHN, IRD UR 206, Université Sorbonne Paris Cité, F-75005 Paris, France;
| | | | - Karine Andrieux
- UMR CNRS 8258—U1267 Inserm, Université de Paris, F-75006 Paris, France;
| | - Muriel Paul
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France; (G.L.G.); (M.P.)
- EpidermE, Université Paris Est Créteil, F-94010 Créteil, France
| |
Collapse
|
7
|
Germer G, Ohigashi T, Yuzawa H, Kosugi N, Flesch R, Rancan F, Vogt A, Rühl E. Improved Skin Permeability after Topical Treatment with Serine Protease: Probing the Penetration of Rapamycin by Scanning Transmission X-ray Microscopy. ACS OMEGA 2021; 6:12213-12222. [PMID: 34056375 PMCID: PMC8154144 DOI: 10.1021/acsomega.1c01058] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 04/07/2021] [Indexed: 05/05/2023]
Abstract
Drug penetration in human skin ex vivo following a modification of skin barrier permeability is systematically investigated by scanning transmission X-ray microscopy. Element-selective excitation is used in the O 1s regime for probing quantitatively the penetration of topically applied rapamycin in different formulations with a spatial resolution reaching <75 nm. The data were analyzed by a comparison of two methods: (i) two-photon energies employing the Beer-Lambert law and (ii) a singular value decomposition approach making use of the full spectral information in each pixel of the X-ray micrographs. The latter approach yields local drug concentrations more reliably and sensitively probed than the former. The present results from both approaches indicate that rapamycin is not observed within the stratum corneum of nontreated skin ex vivo, providing evidence for the observation that this high-molecular-weight drug inefficiently penetrates intact skin. However, rapamycin is observed to penetrate more efficiently the stratum corneum when modifications of the skin barrier are induced by the topical pretreatment with the serine protease trypsin for variable time periods ranging from 2 to 16 h. After the longest exposure time to serine protease, the drug is even found in the viable epidermis. High-resolution micrographs indicate that the lipophilic drug preferably associates with corneocytes, while signals found in the intercellular lipid compartment were less pronounced. This result is discussed in comparison to previous work obtained from low-molecular-weight lipophilic drugs as well as polymer nanocarriers, which were found to penetrate the intact stratum corneum exclusively via the lipid layers between the corneocytes. Also, the role of the tight junction barrier in the stratum granulosum is briefly discussed with respect to modifications of the skin barrier induced by enhanced serine protease activity, a phenomenon of clinical relevance in a range of inflammatory skin disorders.
Collapse
Affiliation(s)
- Gregor Germer
- Physical
Chemistry, Freie Universität Berlin, Arnimallee 22, Berlin 14195, Germany
| | - Takuji Ohigashi
- UVSOR
Synchrotron Facility, Institute for Molecular
Science, Okazaki 444-8585, Japan
| | - Hayato Yuzawa
- UVSOR
Synchrotron Facility, Institute for Molecular
Science, Okazaki 444-8585, Japan
| | - Nobuhiro Kosugi
- UVSOR
Synchrotron Facility, Institute for Molecular
Science, Okazaki 444-8585, Japan
| | - Roman Flesch
- Physical
Chemistry, Freie Universität Berlin, Arnimallee 22, Berlin 14195, Germany
| | | | - Annika Vogt
- Charité-Universitätsmedizin, Berlin 10117, Germany
| | - Eckart Rühl
- Physical
Chemistry, Freie Universität Berlin, Arnimallee 22, Berlin 14195, Germany
| |
Collapse
|
8
|
Le Guyader G, Do B, Vieillard V, Andrieux K, Paul M. Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed. Pharmaceutics 2020; 12:pharmaceutics12111060. [PMID: 33171735 PMCID: PMC7694993 DOI: 10.3390/pharmaceutics12111060] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/03/2020] [Accepted: 11/04/2020] [Indexed: 12/14/2022] Open
Abstract
Rapamycin has been used topically to treat facial angiofibromas associated with tuberous sclerosis for more than a decade. In the absence of a commercial form, a large number of formulations have been clinically tested. However, given the great heterogeneity of these studies, particularly with regard to the response criteria, it was difficult to know the impact and thus to compare the relevance of the formulations used. The objective of this work was therefore to evaluate the link between the diffusion of rapamycin and the physico-chemical characteristics of these different formulations on Strat-M® membranes as well as on human skin using Franz cells. Our results underline the importance of the type of vehicle used (hydrogel > cream > lipophilic ointment), the soluble state of rapamycin and its concentration close to saturation to ensure maximum thermodynamic activity. Thus, this is the first time that a comparative study of the different rapamycin formulations identified in the literature for the management of facial angiofibromas has been carried out using a pharmaceutical and biopharmaceutical approach. It highlights the important parameters to be considered in the development and optimization of topical rapamycin formulations with regard to cutaneous absorption for clinical efficacy.
Collapse
Affiliation(s)
- Guillaume Le Guyader
- Department of Pharmacy, AP-HP, Hôpital Henri Mondor, F-94010 Créteil, France; (B.D.); (V.V.); (M.P.)
- Department of Pharmacy, CHI Creteil, F-94010 Créteil, France
- Correspondence: ; Tel.: +33-1498-147-53
| | - Bernard Do
- Department of Pharmacy, AP-HP, Hôpital Henri Mondor, F-94010 Créteil, France; (B.D.); (V.V.); (M.P.)
- Department of Pharmacy, Université Paris-Saclay, Matériaux et Santé, 92296 Châtenay-Malabry, France
| | - Victoire Vieillard
- Department of Pharmacy, AP-HP, Hôpital Henri Mondor, F-94010 Créteil, France; (B.D.); (V.V.); (M.P.)
| | - Karine Andrieux
- Department of Pharmacy, Université de Paris, CNRS, INSERM, UTCBS, F-75006 Paris, France;
| | - Muriel Paul
- Department of Pharmacy, AP-HP, Hôpital Henri Mondor, F-94010 Créteil, France; (B.D.); (V.V.); (M.P.)
- Department of Pharmacy, EpidermE, Université Paris Est Créteil, F-94010 Créteil, France
| |
Collapse
|
9
|
Vasani R. Topical sirolimus in the treatment of facial angiofibromas. INDIAN JOURNAL OF DRUGS IN DERMATOLOGY 2018. [DOI: 10.4103/ijdd.ijdd_34_18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|